Zuclopenthixol

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Zuclopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.

Zuclopenthixol, also known as Cisordinol, Clopixol, Acuphase, zuclopentixol, is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1962 by Lundbeck. Zuclopenthixol is the cis-isomer of clopenthixol. Zuclopenthixol is not approved for use in the United States. Zuclopenthixol has high affinity for both dopamine D1 and D2 receptors, for α1-adrenoceptors and 5-HT2 receptors but no affinity for cholinergic muscarine receptors. It has weak histamine (H1) receptor affinity and no α2-adrenoceptor blocking activity.

alpha-Clopenthixol; Clopenthixol; Zuclopenthixol

Others

Other Targets

D1; D2

——

——

53772-83-1

400.96

C22H25ClN2OS

98%

DMSO : ≥ 150 mg/mL; 374.10 mM

C1CN(CCN1CC/C=C\1/c2ccccc2Sc2c1cc(cc2)Cl)CCO

2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol

(-20℃)

With Ice Pack

≥ 2 years